drugset / Trial / NCT06283459
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
NaSingle-groupOpen-labelPrevention
Summary
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365).
Timeline
- Start
- 2024-06-04
- Primary completion
- 2025-03-07
- Completion
- 2025-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMNN-101 | Vaccine | 0.5 mg | Intramuscular |
| Subject | IMNN-101 | Vaccine | 1 mg | Intramuscular |
| Subject | IMNN-101 | Vaccine | 2 mg | Intramuscular |